Want to see ZURA full AI Analyst Report?
Top Page
Zura Bio
(NASDAQ:ZURA)
Select Model
Select Model
Rating:46Neutral
Price Target:
$4.00
▼(-33.22% Downside)
Action:Reiterated
Date:09/24/26
The score is held down primarily by very weak financial performance (no revenue, widening losses, and significant cash burn) and bearish technicals (price below key moving averages with negative MACD). Offsetting factors include a low-leverage balance sheet and positive corporate progress with Phase 2 execution and a stated cash runway through at least 2028.
Positive Factors
Debt-free balance sheet
Zero reported debt reduces interest burden and near-term solvency pressure while the increase in equity and assets indicates stronger capitalization. This gives Zura greater flexibility to fund clinical development and absorb setbacks without immediate debt-related constraints.
Negative Factors
No commercial revenue
The absence of revenue means Zura currently lacks an operating income stream to offset research and development costs. Its financial profile therefore depends on external capital and clinical progress, leaving future value highly contingent on successful product development.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt reduces interest burden and near-term solvency pressure while the increase in equity and assets indicates stronger capitalization. This gives Zura greater flexibility to fund clinical development and absorb setbacks without immediate debt-related constraints.
Read all positive factors
Zura Bio (ZURA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$383.32M
Dividend YieldN/A
Average Volume (3M)1.73M
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue GrowthN/A
EPS Growth-65.84%
CountryUS
Employees40
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.13
Shares Outstanding95,829,140
10 Day Avg. Volume1,896,866
30 Day Avg. Volume1,726,112
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-7.60
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.03
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$22.67Price Target Upside278.41% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.77
Revenue Forecast (FY)N/A
Zura Bio Business Overview & Revenue Model
Company Description
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL...
How the Company Makes Money
As a clinical-stage biotechnology company, Zura Bio does not typically generate recurring revenue from commercial product sales. Publicly available information in this context does not provide specific, company-confirmed detail on established reve...
Zura Bio Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
68
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -16.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -85.76M | -68.60M | -52.39M | -60.56M | -27.33M | 8.42M |
| Net Income | -85.74M | -68.65M | -52.40M | -60.36M | -25.74M | 8.42M |
Balance Sheet | ||||||
| Total Assets | 213.40M | 113.95M | 179.53M | 100.84M | 5.26M | 140.55M |
| Cash, Cash Equivalents and Short-Term Investments | 205.13M | 109.41M | 176.50M | 99.81M | 1.57M | 729.22K |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 7.76M | 0.00 |
| Total Liabilities | 16.32M | 12.41M | 19.51M | 21.29M | 27.32M | 10.35M |
| Stockholders Equity | 197.09M | 101.54M | 146.81M | 59.33M | -32.06M | 130.20M |
Cash Flow | ||||||
| Free Cash Flow | -77.63M | -64.93M | -28.15M | -23.05M | -13.20M | -1.10M |
| Operating Cash Flow | -77.55M | -64.81M | -28.08M | -15.05M | -1.20M | -1.10M |
| Investing Cash Flow | -86.00K | -113.00K | -5.08M | -8.00M | -12.00M | -139.38M |
| Financing Cash Flow | 128.28M | -2.16M | 109.84M | 121.29M | 14.77M | 141.21M |
Zura Bio Technical Analysis
Negative
5.99
Price Trends
5.36
Negative
4.95
Negative
5.32
Negative
Market Momentum
-0.42
Positive
31.83
Neutral
26.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZURA, the sentiment is Negative. The current price of 5.99 is above the 20-day moving average (MA) of 4.89, above the 50-day MA of 5.36, and above the 200-day MA of 5.32, indicating a bearish trend. The MACD of -0.42 indicates Positive momentum. The RSI at 31.83 is Neutral, neither overbought nor oversold. The STOCH value of 26.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ZURA.
Zura Bio Risk Analysis
Zura Bio disclosed 82 risk factors in its most recent earnings report. Zura Bio reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Zura Bio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $504.84M | 18.52 | 20.85% | ― | -2.86% | -46.26% | |
52 Neutral | $227.84M | -3.70 | -68.44% | ― | 19.49% | -4.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $383.32M | -3.68 | -54.98% | ― | ― | -65.84% | |
42 Neutral | $104.13M | -2.31 | -94.14% | ― | -0.11% | -13.99% | |
41 Neutral | $1.08B | -0.06 | -91.63% | ― | ― | 69.48% |
* Healthcare Sector Average
ZURA
Zura Bio
4.16
0.12
2.97%
PBYI
Puma Biotechnology
9.93
4.66
88.43%
PRQR
ProQR
1.66
-0.50
-23.15%
CLLS
Cellectis SA
1.51
-1.78
-54.10%
VOR
Vor Biopharma
19.08
-20.18
-51.40%
Zura Bio Corporate Events
Business Operations and StrategyProduct-Related Announcements
Zura Bio Updates Tibulizumab Progress and Cash Outlook
Positive
Aug 17, 2026
On August 17, 2026, Zura Bio released an updated corporate presentation outlining progress on tibulizumab, a bispecific antibody targeting IL-17 and BAFF, and positioning it as a “biologically de-risked” candidate for immune-mediated d...
Business Operations and StrategyFinancial Disclosures
Zura Bio Advances Tibulizumab Phase 2 Trials and Pipeline
Positive
Aug 11, 2026
On August 11, 2026, Zura Bio reported second-quarter 2026 results and detailed progress across its pipeline of dual-pathway antibody therapies for autoimmune and inflammatory diseases. The company highlighted the completion of enrollment in its tw...
Business Operations and StrategyFinancial DisclosuresProduct-Related Announcements
Zura Bio Highlights Tibulizumab Progress and Funding Runway
Positive
Jul 1, 2026
On July 1, 2026, Zura Bio released an updated corporate presentation outlining progress with its lead asset tibulizumab, a bispecific antibody designed to modulate both B-cell and T-cell driven pathobiology in complex autoimmune diseases. The comp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.